SIENA, SALVATORE
SIENA, SALVATORE
Dipartimento di Oncologia ed Emato-Oncologia
Clinicopathological characterisation of MTAP alterations in gastrointestinal cancers
2025 G. Mauri, G. Patelli, L. Roazzi, E. Valtorta, A. Amatu, G. Marrapese, E. Bonazzina, F. Tosi, K. Bencardino, G. Ciarlo, E. Mariella, S. Marsoni, A. Bardelli, E. Bonoldi, A. Sartore-Bianchi, S. Siena
Circulating blood biomarkers for minimal residual disease in hepatocellular carcinoma: A systematic review
2025 E. Galli, G. Patelli, F. Villa, N. Gri, C. Mazzarelli, I. Mangoni, C. Sgrazzutti, S. Ghezzi, A. Sartore-Bianchi, L.S. Belli, L. De Carlis, A. Vanzulli, S. Siena, K. Bencardino
Summary of Research: Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02
2025 A. Oaknin, J. Lee, V. Makker, D. Oh, S. Banerjee, A. González-Martín, K.H. Jung, I. Ługowska, L. Manso, A. Manzano, B. Melichar, S. Siena, D. Stroyakovskiy, A. Fielding, S. Puvvada, A. Smith, F. Meric-Bernstam
The role of anti-EGFR rechallenge in metastatic colorectal cancer, from available data to future developments: A systematic review
2024 D. Ciardiello, G. Mauri, A. Sartore-Bianchi, S. Siena, M.G. Zampino, N. Fazio, A. Cervantes
Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial
2024 K. Raghav, S. Siena, A. Takashima, T. Kato, M. Van den Eynde, F. Pietrantonio, Y. Komatsu, H. Kawakami, M. Peeters, T. Andre, S. Lonardi, K. Yamaguchi, J. Tie, C.G. Castro, H. Hsu, J.H. Strickler, T. Kim, Y. Cha, D. Barrios, Q. Yan, T. Kamio, K. Kobayashi, A. Boran, M. Koga, J.D. Allard, T. Yoshino
Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02
2024 A. Oaknin, J. Lee, V. Makker, D. Oh, S. Banerjee, A. González-Martín, K.H. Jung, I. Ługowska, L. Manso, A. Manzano, B. Melichar, S. Siena, D. Stroyakovskiy, A. Fielding, S. Puvvada, A. Smith, F. Meric-Bernstam
Prediction of homologous recombination deficiency identifies colorectal tumors sensitive to PARP inhibition
2024 G. Corti, K. Buzo, E. Berrino, M. Miotto, M.C. Aquilano, M. Lentini, S.E. Bellomo, A. Lorenzato, A. Bartolini, G. Mauri, L. Lazzari, M. Russo, F. Di Nicolantonio, S. Siena, S. Marsoni, C. Marchiò, A. Bardelli, S. Arena
Brief Report: Updated Efficacy and Safety Data From an Integrated Analysis of Entrectinib in Locally Advanced/Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer
2024 Y. Fan, A. Drilon, C. Chiu, H.H.F. Loong, S. Siena, M. Krzakowski, R. Dziadziuszko, H. Zeuner, C. Xue, M.G. Krebs
A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study
2024 M. Niger, F. Nichetti, L. Fornaro, C. Pircher, F. Morano, F. Palermo, L. Rimassa, T. Pressiani, R. Berardi, A.C. Gardini, E. Sperti, L. Salvatore, D. Melisi, F. Bergamo, S. Siena, S. Mosconi, R. Longarini, G. Arcangeli, S. Corallo, L. Delliponti, S. Tamberi, E. Fea, G. Brandi, I.G. Rapposelli, M. Salati, P. Baili, R. Miceli, S. Ljevar, I. Cavallo, E. Sottotetti, A. Martinetti, M.D.D. Busset, C. Sposito, M. Di Bartolomeo, F. Pietrantonio, F. de Braud, V. Mazzaferro
Ongoing Clinical Trials and Future Research Scenarios of Circulating Tumor DNA for the Treatment of Metastatic Colorectal Cancer
2024 L. Roazzi, G. Patelli, K.B. Bencardino, A. Amatu, E. Bonazzina, F. Tosi, B. Amoruso, A. Bombelli, S. Mariano, S. Stabile, C. Porta, S. Siena, A. Sartore-Bianchi
Curative immune checkpoint inhibitors therapy in patients with mismatch repair-deficient locally advanced rectal cancer: a real-world observational study
2024 F. Tosi, L. Salvatore, E. Tamburini, S. Artale, S. Lonardi, S. Marchetti, A. Pastorino, F. Pietrantonio, A. Puccini, F.L. Rojas-Llimpe, B. Vincenzi, S. Mariano, F. Negri, K. Bencardino, C. Pinto, C. Aschele, S. Siena
Activity of osimeRTInib in non-small-cell lung Cancer with UNcommon epidermal growth factor receptor mutations: retrospective Observational multicenter study (ARTICUNO)
2024 E.G. Pizzutilo, A.G. Agostara, S. Oresti, D. Signorelli, S. Stabile, C. Lauricella, V. Motta, A. Amatu, L. Ruggieri, M. Brambilla, M. Occhipinti, C. Proto, R. Giusti, M. Filetti, C. Genova, G. Barletta, F. Gelsomino, C. Bennati, M. Siringo, G.R. Di Fazio, M. Russano, M. Montrone, E. Gariazzo, E. Roca, P. Bordi, A. Delmonte, A. Scimone, L. Belluomini, F. Mazzoni, A. Carta, G. Pelizzari, G. Viscardi, F. Morgillo, A. Gelibter, S. Gori, R. Berardi, D. Cortinovis, A. Ardizzoni, S.M. Veronese, A. Sartore-Bianchi, L.G. Giannetta, G. Cerea, S. Siena
HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01
2024 S. Siena, K. Raghav, T. Masuishi, K. Yamaguchi, T. Nishina, E. Elez, J. Rodriguez, I. Chau, M. Di Bartolomeo, H. Kawakami, F. Suto, M. Koga, K. Inaki, Y. Kuwahara, I. Takehara, D. Barrios, K. Kobayashi, A. Grothey, T. Yoshino
Anti-EGFR Rechallenge in Patients With Refractory ctDNA RAS/BRAF wt Metastatic Colorectal Cancer: A Nonrandomized Controlled Trial
2024 D. Ciardiello, E. Martinelli, T. Troiani, G. Mauri, D. Rossini, G. Martini, S. Napolitano, V. Famiglietti, S. Del Tufo, G. Masi, D. Santini, A. Avallone, F. Pietrantonio, S. Lonardi, M. Di Maio, M.G. Zampino, N. Fazio, A. Bardelli, S. Siena, C. Cremolini, A. Sartore-Bianchi, F. Ciardiello
Tolerance to colibactin correlates with homologous recombination proficiency and resistance to irinotecan in colorectal cancer cells
2024 A. Sogari, E. Rovera, G. Grasso, E. Mariella, N.M. Reilly, S. Lamba, G. Mauri, E. Durinikova, P.P. Vitiello, A. Lorenzato, M. Avolio, E. Piumatti, E. Bonoldi, M.C. Aquilano, S. Arena, A. Sartore-Bianchi, S. Siena, L. Trusolino, M. Donalisio, M. Russo, F. Di Nicolantonio, D. Lembo, A. Bardelli
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial
2024 F. Meric-Bernstam, V. Makker, A. Oaknin, D. Oh, S. Banerjee, A. González-Martín, K.H. Jung, I. Ługowska, L. Manso, A. Manzano, B. Melichar, S. Siena, D. Stroyakovskiy, A. Fielding, Y. Ma, S. Puvvada, N. Shire, J. Lee
Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study
2024 B.T. Li, F. Meric-Bernstam, A. Bardia, Y. Naito, S. Siena, P. Aftimos, I. Anderson, G. Curigliano, M. de Miguel, M. Kalra, D. Oh, J.O. Park, S. Postel-Vinay, S.Y. Rha, T. Satoh, I. Spanggaard, F. Michelini, A. Smith, K.K. Machado, C. Saura
Characteristics and Survival Outcomes of Patients With Metastatic RET Fusion-Positive Solid Tumors Receiving Non-RET Inhibitor Standards of Care in a Real-World Setting
2024 A. Hackshaw, O. Fajardo, U. Dafni, H. Gelderblom, P. Garrido, S. Siena, M.H. Taylor, W. Bordogna, C. Nikolaidis
A Comparative Study of Methyl-BEAMing and Droplet Digital PCR for MGMT Gene Promoter Hypermethylation Detection
2024 M. Macagno, V. Pessei, N. Congiusta, L. Lazzari, S.E. Bellomo, F. Idrees, A. Cavaliere, F. Pietrantonio, A. Raimondi, E. Gusmaroli, M.G. Zampino, L. Gervaso, D. Ciardiello, G. Mondello, A. Santoro, N. Personeni, E. Bonoldi, M.C. Aquilano, E. Valtorta, S. Siena, A. Sartore-Bianchi, A. Amatu, E.F. Bonazzina, K.B. Bencardino, G. Serini, S. Marsoni, L. Barault, F. Di Nicolantonio, F. Maione
Early-onset cancers: Biological bases and clinical implications
2024 G. Mauri, G. Patelli, A. Sartore-Bianchi, S. Abrignani, B. Bodega, S. Marsoni, V. Costanzo, A. Bachi, S. Siena, A. Bardelli